Header Logo

Connection

Didem Saygin to Rituximab

Back to Details
This is a "connection" page, showing publications Didem Saygin has written about Rituximab.
Didem Saygin
Connection Strength
0.056
Rituximab
  1. Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles. Rheumatology (Oxford). 2023 Nov 02; 62(11):3680-3689.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.